KR100847944B1 - Ｃｄ40 항체 제제 및 방법 - Google Patents

Ｃｄ40 항체 제제 및 방법 Download PDF

Info

Publication number
KR100847944B1
KR100847944B1 KR1020067012364A KR20067012364A KR100847944B1 KR 100847944 B1 KR100847944 B1 KR 100847944B1 KR 1020067012364 A KR1020067012364 A KR 1020067012364A KR 20067012364 A KR20067012364 A KR 20067012364A KR 100847944 B1 KR100847944 B1 KR 100847944B1
Authority
KR
South Korea
Prior art keywords
antibody
tumor
antibodies
cancer
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067012364A
Other languages
English (en)
Korean (ko)
Other versions
KR20070012626A (ko
Inventor
바헤 베디안
존 다니엘 쿠스마노
로날드 폴 글래듀
Original Assignee
화이자 프로덕츠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100847944(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 프로덕츠 인크. filed Critical 화이자 프로덕츠 인크.
Publication of KR20070012626A publication Critical patent/KR20070012626A/ko
Application granted granted Critical
Publication of KR100847944B1 publication Critical patent/KR100847944B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020067012364A 2003-12-22 2004-12-09 Ｃｄ40 항체 제제 및 방법 Expired - Fee Related KR100847944B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22
US60/531,639 2003-12-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087004912A Division KR20080023766A (ko) 2003-12-22 2004-12-09 Ｃｄ40 항체 제제 및 방법

Publications (2)

Publication Number Publication Date
KR20070012626A KR20070012626A (ko) 2007-01-26
KR100847944B1 true KR100847944B1 (ko) 2008-07-22

Family

ID=34738672

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067012364A Expired - Fee Related KR100847944B1 (ko) 2003-12-22 2004-12-09 Ｃｄ40 항체 제제 및 방법
KR1020087004912A Ceased KR20080023766A (ko) 2003-12-22 2004-12-09 Ｃｄ40 항체 제제 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087004912A Ceased KR20080023766A (ko) 2003-12-22 2004-12-09 Ｃｄ40 항체 제제 및 방법

Country Status (20)

Country Link
US (4) US20050136055A1 (enExample)
EP (3) EP2218461B1 (enExample)
JP (3) JP2007515469A (enExample)
KR (2) KR100847944B1 (enExample)
CN (2) CN102552905A (enExample)
AU (1) AU2004308749B2 (enExample)
BR (1) BRPI0418029B8 (enExample)
CA (2) CA2549652C (enExample)
DK (1) DK2218461T3 (enExample)
ES (1) ES2580002T3 (enExample)
HU (1) HUE027717T2 (enExample)
IL (2) IL175540A (enExample)
NO (1) NO343797B1 (enExample)
NZ (2) NZ583179A (enExample)
PL (1) PL2218461T3 (enExample)
RU (1) RU2355421C2 (enExample)
SI (1) SI2218461T1 (enExample)
TW (1) TWI359671B (enExample)
WO (1) WO2005063289A1 (enExample)
ZA (1) ZA200603804B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2006329944A1 (en) * 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using CD40 binding agents
US7993648B2 (en) 2006-05-03 2011-08-09 The Regents of the Universitry of Colorado Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20110311525A1 (en) * 2008-08-29 2011-12-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CN106928362B (zh) 2011-04-29 2021-10-26 埃派斯进有限公司 抗-cd40抗体及其使用方法
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
EP3995507B1 (en) 2013-08-08 2023-10-04 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
KR20240073140A (ko) 2014-10-29 2024-05-24 씨젠 인크. 비-푸코실화된 항-cd40 항체의 용량 및 투여
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
PL3426271T3 (pl) 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
PT3468997T (pt) 2016-06-08 2023-12-07 Debra Zack Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018085734A1 (en) 2016-11-04 2018-05-11 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
KR102019033B1 (ko) * 2016-11-11 2019-09-06 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP3632933A4 (en) * 2017-06-01 2021-03-03 Seoul National University R & DB Foundation Novel anti-cd40 antibodies and use thereof
JP2020521788A (ja) * 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 免疫アゴニストの投与経路
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
AU2019255781A1 (en) * 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
CA3114567A1 (en) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
CN116063495A (zh) * 2018-09-28 2023-05-05 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
BR112021010414A2 (pt) * 2018-11-30 2021-09-08 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
MX2021008305A (es) 2019-01-11 2021-08-24 Novartis Ag Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
BR112022010680A2 (pt) 2019-12-03 2022-08-16 Evotec Int Gmbh Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN116234575A (zh) * 2020-06-04 2023-06-06 赛尔疫苗私人有限公司 激动剂抗cd40抗体
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
WO2022037662A1 (en) * 2020-08-21 2022-02-24 Wuxi Biologics (Shanghai) Co. Ltd. Cd40 agonistic antibody and method of use
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040170A2 (en) * 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0724456B1 (en) * 1993-10-01 2003-12-10 Immunex Corporation Antibodies to cd40
AU680102B2 (en) * 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3919235B2 (ja) * 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
GEP20063774B (en) * 1999-06-01 2006-03-27 Biogen Idec Inc Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
ATE395413T1 (de) * 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040170A2 (en) * 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40

Also Published As

Publication number Publication date
ZA200603804B (en) 2007-09-26
HUE027717T2 (en) 2016-10-28
TW200521142A (en) 2005-07-01
JP2011184446A (ja) 2011-09-22
RU2355421C2 (ru) 2009-05-20
AU2004308749B2 (en) 2010-10-28
JP5634321B2 (ja) 2014-12-03
CA2549652C (en) 2013-11-12
US20120263732A1 (en) 2012-10-18
NO20063373L (no) 2006-09-21
AU2004308749A1 (en) 2005-07-14
US20110104182A1 (en) 2011-05-05
US20050136055A1 (en) 2005-06-23
IL201409A0 (en) 2010-05-31
SI2218461T1 (sl) 2016-08-31
NZ547162A (en) 2010-03-26
IL175540A0 (en) 2006-09-05
CN102552905A (zh) 2012-07-11
TWI359671B (en) 2012-03-11
ES2580002T3 (es) 2016-08-18
WO2005063289A1 (en) 2005-07-14
EP2218461A1 (en) 2010-08-18
RU2006120950A (ru) 2008-01-27
BRPI0418029B8 (pt) 2021-05-25
IL175540A (en) 2011-10-31
DK2218461T3 (en) 2016-05-17
EP2218461B1 (en) 2016-04-20
EP3081933A1 (en) 2016-10-19
BRPI0418029B1 (pt) 2018-12-26
KR20070012626A (ko) 2007-01-26
EP1706143A1 (en) 2006-10-04
NO343797B1 (no) 2019-06-11
BRPI0418029A (pt) 2007-04-17
US20090311254A1 (en) 2009-12-17
KR20080023766A (ko) 2008-03-14
CA2704300A1 (en) 2005-07-14
JP2007515469A (ja) 2007-06-14
JP2014205692A (ja) 2014-10-30
CA2549652A1 (en) 2005-07-14
CN1897971A (zh) 2007-01-17
NZ583179A (en) 2011-06-30
PL2218461T3 (pl) 2016-09-30

Similar Documents

Publication Publication Date Title
KR100847944B1 (ko) Ｃｄ40 항체 제제 및 방법
TW202228777A (zh) 對抗pd-1及pd-l1之拮抗劑與輻射療法組合之治療方法
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
KR20220042067A (ko) Gm-csf 길항제를 사용한 암의 치료
TW202216193A (zh) 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
JP2022534494A (ja) 抗ｃｄ４０抗体の安全な投与を提供する方法
HK1172823A (en) Cd40 antibody formulation and methods
CN112439060B (zh) Pd-l1免疫疗法的新用途
MXPA06006153A (en) Cd40 antibody formulation and methods
US20230279132A1 (en) Treatment of b cell malignancies

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130628

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20140627

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20170629

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220717

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220717